Improvement of the efficiency of treatment in patients with coronary artery disease and metabolic syndrome after percutaneous coronary intervention for acute coronary syndrome without ST-segment elevation.
DOI:
https://doi.org/10.26641/2307-0404.2016.2.72151Keywords:
percutaneous coronary intervention, metabolic syndrome, QuercetinAbstract
The paper presents original data on improvement of effectiveness of treatment (reduction of systemic inflammation, stabilization of lipid metabolism, improvment of quality of life) in patients with coronary artery disease (CAD) and metabolic syndrome (MS), who underwent primary percutaneous coronary intervention (PCI) for acute coronary syndrome without ST-segment elevation (ACS nST) by adding quercetin to basic therapy, 40 mg 3 times a day during the 12,07 ± 1,51 months. The reduction of a high sensitive C-reactive proteins (hs-CRP), (2,51 ± 0,93, nmol / L., versus 3,12 ± 0,43, nmol / L.), (p = 0,0007) and low-density lipoproteins (LDL), (4,01 ± 0,36, mmol / L., versus 4,29 ± 0,71, mmol / L.), (p=0,049) in the main group II (n = 33) as compared with the control group I (n=31), respectively,as well as thrombin: 5,96 ± 1,89, ng / mL. in group I as compared with 3,91 ± 1,43, ng / mL. in group II, (p=0,0002) was revealed. High density lipoproteins (HDL) were significantly greater (p = 0,049) in the group II (1,35 ± 0,41, mmol / L.) in comparison with the group I (1,17 ± 0,34, mmol / L.).
References
Bratus' VV, Taleva TV, Shumakov VA. [Obesity, in¬sulin resistance, metabolic syndrome: basic and clinical as¬pects]. 2nd ed. Kiev: Chetverta khvilya; 2009;416. Russian.
Dogolіch OІ, Voloshin OІ. [Flavonoid quercetin as a means of preventing cardiovascular risk in patients with gout with high comorbidity]. Fіtoterapіya. Chasopis. 2014;4:88-90. Ukrainian.
Dolzhenko MN. [On the question of the ap-propriateness of metabolic cardioprotection in an era of evidence-based medicine]. Zhurnal suchasnogo lіkarja. 2012;2(3):3-6. Russian.
Kakorin SV, Kononec EN. [Clinical case of acute coronary syndrome in patients with diabetes type 2]. Medicinskij sovet. 2015;8:22-30. Russian.
Shumakova VO, Parhomenko OM, editors. [The recommendations of the Ukrainian Association of Car-diologists for the treatment of patients with acute co-ronary syndrome without persistent ST-segment ele-vation]. Kiev: Chetverta hvilja; 2013;50. Ukrainian.
Tarahovskij JuS, Kim JuA, Abdrasilov BS, Muzafarov EN. [Flavonoids: biochemistry, biophysics, medicine]. Pushhino: Sunchrobook. 2013;311. Russian.
Shhegol'kov AM, Jaroshenko VP, Shakula AV. [Comprehensive medical rehabilitation of patients with myocardial infarction in the functional and recovery period with the inclusion of bioflavonoids]. Lechashhij vrach. 2010;4:77-81. Russian.
Anselmino M, Malmberg K, Ryden L, Ohrvik J. A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease. Diab Vasc Dis Res. 2009;6(2):62-70.
Ozyazicioglu A, Yalcinskaya S, Vural A, Yumun G, Bozkurt O. Effects of metabolic syndrome on early mortality and morbidity in coronary artery bypass graft patients. J Int Med Res. 2010;38(1):202-7.
Grundy S, Brewer H, Cleeman J, Smith S, Len¬fant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute. American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8.
Metabolic Syndrome: New Insights for the Healthcare Professional: 2013 Edition. Q. Ashton Acton, editor. Atlanta: ScholarlyEditions. 2013;115.
Mosawy S. Effect of the flavonol quercetin on human platelet function: a review. Food and Public Health. 2015;5(1):1-9.
Berghammer M, Karlsson J, Ekman I, Eriksson P, Dellborg M. Self-reported health status (EQ-5D) in adults with congenital heart disease. Int J Cardiol. 2013;165:537-43.
Soares R, Costa C. Oxidative Stress, Inflam-mation and Angiogenesis in the Metabolic Syndrome. Porto: Springer Science & Business Media. 2009;210.
Tsimikas S, Willerson J, Ridker P. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47:19-31.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
